Supplemental material

BMJ Publishing Group Limited (BMJ) disclaims all liability and responsibility arising from any reliance placed on this supplemental material which has been supplied by the author(s)

BMJ Open

Supplementary material online

Supplementary Figure S1

Distribution of propensity scores between statin and non-statin groups in the overall cohort.

Supplementary Table S1

Patient characteristics of the propensity score matched and unmatched groups

	Matched group n=1872	Unmatched group n=716	*P*-value
Preprocedural variables			
Age, years	84.2±5.1	84.6±5.4	0.08
Male, n (%)	532 (28.4%)	263 (36.7%)	<0.01
Body surface area, m^2	1.43±0.17	1.42±0.17	0.16
NYHA class 3 or 4, n (%)	919 (49.1%)	402 (56.2%)	<0.01
Clinical Frailty Scale	3.8±1.2	4.2±1.4	<0.01
Smoking, *n* (%)	364 (19.4%)	160 (22.4%)	0.10
Diabetes mellitus, *n* (%)	402 (21.5%)	153 (21.4%)	0.95
Hypertension, *n* (%)	1497 (80.0%)	493 (68.9%)	<0.01
Chronic kidney disease, *n* (%)	1291 (69.0%)	518 (72.4%)	0.09
Atrial fibrillation, *n* (%)	364 (19.4%)	185 (25.8%)	<0.01

2

Coronary artery disease, *n* (%)	750 (40.1%)	204 (28.5%)	<0.01
Previous myocardial infarction, *n* (%)	96 (5.1%)	62 (8.7%)	<0.01
Previous percutaneous coronary intervention, *n* (%)	487 (26.0%)	139 (19.4%)	<0.01
Previous coronary artery bypass grafting, *n* (%)	117 (6.3%)	52 (7.3%)	0.36
Peripheral artery disease, *n* (%)	264 (14.1%)	113 (15.8%)	0.28
Previous stroke, *n* (%)	9 (0.5%)	3 (0.4%)	0.98
STS risk score	7.7±5.7	9.8±9.2	<0.01
Renin-angiotensin inhibitor, *n* (%)	1084 (57.9%)	303 (42.3%)	<0.01
Beta blocker, *n* (%)	637 (34.0%)	243 (33.9%)	0.97
eGFR, mL/min/1.73 m^2	52.0±19.1	49.7±20.1	<0.01
Haemoglobin, g/dL	11.3±1.6	11.2±1.7	0.16
Procedural variables			
Transfemoral approach, *n* (%)	1554 (83.0%)	613 (85.6%)	0.11

Supplemental material

BMJ Publishing Group Limited (BMJ) disclaims all liability and responsibility arising from any reliance placed on this supplemental material which has been supplied by the author(s)

BMJ Open

Local anaesthesia, *n* (%)	1448 (77.4%)	530 (74.0%)	0.08
Contrast volume, mL	116.1±58.6	114.1±58.2	0.43
Fluoroscopy time, min	21.4±11.4	21.2±10.5	0.66
Procedure time, min	81.0±43.3	80.3±50.9	0.72

CT, computed tomography; eGFR, estimated glomerular filtration rate; NYHA, New York

Heart Association; STS, Society of Thoracic Surgeons.

BMJ Publishing Group Limited (BMJ) disclaims all liability and responsibility arising from any reliance placed on this supplemental material which has been supplied by the author(s)

4

Supplemental material

BMJ Publishing Group Limited (BMJ) disclaims all liability and responsibility arising from any reliance placed on this supplemental material which has been supplied by the author(s)

BMJ Open

Supplementary Table S2

In-hospital outcomes of the propensity score-matched and -unmatched groups

	Matched group n=1872	Unmatched group n=716	*P*-value
All-cause mortality, *n* (%)	43 (2.3%)	27 (3.8%)	<0.01
Acute kidney injury, *n* (%)	201 (10.7%)	88 (12.3%)	0.27
Bleeding, *n* (%)	421 (22.5%)	199 (27.8%)	<0.01
Stroke, *n* (%)	43 (2.3%)	18 (2.5%)	0.75
Vascular complication, *n* (%)	168 (9.0%)	65 (9.1%)	0.93